Allison Jennie Dunshie, OTR | |
1002 E Central Blvd, Anadarko, OK 73005-4405 | |
(405) 247-0527 | |
(405) 247-8258 |
Full Name | Allison Jennie Dunshie |
---|---|
Gender | Female |
Speciality | Occupational Therapist |
Location | 1002 E Central Blvd, Anadarko, Oklahoma |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1770008245 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225X00000X | Occupational Therapist | 1900 (Oklahoma) | Primary |
Mailing Address | Practice Location Address |
---|---|
Allison Jennie Dunshie, OTR 1816 Lois Lynn Ln, Edmond, OK 73003-3764 Ph: (405) 821-3417 | Allison Jennie Dunshie, OTR 1002 E Central Blvd, Anadarko, OK 73005-4405 Ph: (405) 247-0527 |
News Archive
A team of University of California, Los Angeles researchers found that positron emission tomography (PET) can provide important information on the relationship between heart function and obesity. Their findings were reported at the Society of Nuclear Medicine's 52nd Annual Meeting June 18–22 in Toronto.
ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced that Roche is implementing a "three-pronged approach" to developing trastuzumab emtansine (T-DM1) for early stage HER2-positive breast cancer, according to plans outlined by Roche at its 2012 ASCO analyst event.
A new autism curriculum developed by the Centers for Disease Control and Prevention, and endorsed by the American Academy of Pediatrics (AAP), will be launched at the 2011 AAP National Conference & Exhibition (NCE) in Boston Oct. 15-17.
20/20 GeneSystems, Inc. announced today at the AdvaMed MedTech Conference in Washington, D.C. that the company has been awarded nearly $3 million in grants from the National Cancer Institute's (NCI) Small Business Innovative Research (SBIR) Program to develop tests to help oncologists predict the effectiveness of targeted cancer therapies.
Researchers report that low levels of sodium, known as hyponatremia, prior to transplantation does not increase the risk of death following liver transplant. Full findings are published in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
› Verified 7 days ago